Comparing the plasma levels of sHLA-G in patients with primary and relapmed gliomas, our results revealed higher levels of sHLA-G in relapsed glioma patients (Median ± IQR: 27.57 U/mL ± 35.79) than in primary gliomas (median ± IQR: 46.66 U/mL ± 54.66), however, the difference was not statistically significant (p = 0.071). This evidence concerns the gene HLA-G and glioma.